Therefore, detecting HAND2-AS1 expression in clinical samples covering benign and malignancy, initial and advanced stages, primary and recurrent cases are necessary for drawing the global pictures of HAND2-AS1 regulation networks in bladder cancer. This evidence concerns the gene HAND2 and urinary bladder cancer.